Primary Processor Scombrotoxin Controls - Overview and Testing at Receiving

This video presents FDA’s recommendations for primary processors to control the hazard of scombrotoxin (histamine) formation when receiving raw scombrotoxin-forming fish species. FDA recommends two primary processor control strategies; the Histamine Testing Control Strategy and the Harvest Vessel Record Control Strategy. This video focuses on HACCP control elements related to internal temperature measurements, sensory examinations, and, where applicable, histamine testing activities associated with both control strategies A separate video presents primary processor controls specific to the development and use of harvest vessel records as a primary processor HACCP control.

FDA Fish and Fishery Products and Hazards Controls Guidance, 4th Edition:  Introduction and Overview
▶︎

FDA Fish and Fishery Products and Hazards Controls Guidance, 4th Edition: Introduction and Overview

Employees are the FIRST Line of Food Defense (English)
▶︎

Employees are the FIRST Line of Food Defense (English)

FDA Grand Rounds - Pharmacovigilance in Practice: From Safety Signals to Regulatory Action
▶︎

FDA Grand Rounds - Pharmacovigilance in Practice: From Safety Signals to Regulatory Action

CDRH - REdI Annual Conference 2026: Innovative Regulatory Strategies to Advance Medical Products
▶︎

CDRH - REdI Annual Conference 2026: Innovative Regulatory Strategies to Advance Medical Products

CDER - REdI Annual Conference 2026: Innovative Regulatory Strategies to Advance Medical Products
▶︎

CDER - REdI Annual Conference 2026: Innovative Regulatory Strategies to Advance Medical Products

AGDD 2025 | D2S03 - Common Deficiencies and Resolutions: Complex Drug Substance/Excipients/Products
▶︎

AGDD 2025 | D2S03 - Common Deficiencies and Resolutions: Complex Drug Substance/Excipients/Products

Commissioner’s National Priority Voucher (CNPV) Pilot Program Public Hearing
▶︎

Commissioner’s National Priority Voucher (CNPV) Pilot Program Public Hearing

OTP Town Hall: Best Practices for Preparing BLA Submissions for Cell and Gene Therapy Products
▶︎

OTP Town Hall: Best Practices for Preparing BLA Submissions for Cell and Gene Therapy Products

ClinicalTrials.gov: Essentials for Academic Medical Centers – Pre-recorded Training Video
▶︎

ClinicalTrials.gov: Essentials for Academic Medical Centers – Pre-recorded Training Video

Conversations on Cancer: Patient first = Project Facilitate
▶︎

Conversations on Cancer: Patient first = Project Facilitate

AGDD 2025 | D1S02 - Session 2: Q&A Discussion Panel
▶︎

AGDD 2025 | D1S02 - Session 2: Q&A Discussion Panel

Understanding the Nutrition Facts Label, the Updated “Healthy” Claim, and Other Nutrition Claims
▶︎

Understanding the Nutrition Facts Label, the Updated “Healthy” Claim, and Other Nutrition Claims

AGDD 2025 | D2S04 - Nitrosamines: Known Issues and Practical Advice
▶︎

AGDD 2025 | D2S04 - Nitrosamines: Known Issues and Practical Advice

FDA Direct: These 9 Drugs Were Awarded National Priority Vouchers
▶︎

FDA Direct: These 9 Drugs Were Awarded National Priority Vouchers

AGDD 2025 | D1S01 - Product-Specific Guidance for Complex Products: From Research to Standards
▶︎

AGDD 2025 | D1S01 - Product-Specific Guidance for Complex Products: From Research to Standards

AGDD 2025 | D1S02 - Novel Bioequivalence Study Design Recommendations
▶︎

AGDD 2025 | D1S02 - Novel Bioequivalence Study Design Recommendations

VRBPAC -- May 28 Meeting
▶︎

VRBPAC -- May 28 Meeting

AGDD 2025 | D2S03-1 Session 3: Q&A Discussion Panel
▶︎

AGDD 2025 | D2S03-1 Session 3: Q&A Discussion Panel

AGDD 2025 | D1S01 – Session 1: Q&A Discussion Panel
▶︎

AGDD 2025 | D1S01 – Session 1: Q&A Discussion Panel

AGDD 2025 | D2S04 – Session 4: Q&A Discussion Panel
▶︎

AGDD 2025 | D2S04 – Session 4: Q&A Discussion Panel